Investigating new treatments for high-grade serous ovarian cancer and triple-negative breast cancer

Who could benefit from this research

What this research studies

This research focuses on the role of protein arginine methyltransferases (PRMTs) in high-grade serous ovarian cancer and triple-negative breast cancer. It aims to evaluate new inhibitors that target these proteins, which are found at elevated levels in cancer cells and linked to poor outcomes. The study will explore how these inhibitors can be combined with other therapies to improve treatment effectiveness. Patients may benefit from a better understanding of how to use these new drugs in combination with existing treatments.

Why it matters

Where this research is happening

• University of Pennsylvania
  Philadelphia, United States Active

Researchers

• Principal investigator: Zhang, Lin — University of Pennsylvania
• Study coordinator: Zhang, Lin

Related research

Other NIH-funded projects on the same topics.

• PRMT inhibitors as a new approach for ovarian and breast cancer

  A cancer research project tests whether drugs that block arginine methylation can help treat high-grade serous ovarian cancer and triple-negative breast cancer.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11383146

• Blocking arginine-modifying enzymes for aggressive ovarian and triple-negative breast cancer

  Researchers are testing whether drugs that block PRMT enzymes, used with other cancer medicines, can better control high-grade serous ovarian cancer and triple-negative breast cancer.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11179474

• Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

  This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621786

• Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

  A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.

  NIH research Baltimore VA Medical Center · Baltimore, United States · NIH-11608792

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.